- New real-world analysis highlights
unmet medical need in GI cancer patients with TSC1/2
alterations-
LOS
ANGELES, Jan. 19, 2024 /PRNewswire/ -- Aadi
Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company
focused on developing and commercializing precision therapies for
patients with mTOR pathway alterations, today announced poster
presentations at the 2024 American Society of Clinical Oncology
(ASCO) Gastrointestinal (GI) Cancers Symposium, taking
place January 18-20, 2024, in San Francisco,
CA.
Abstract and poster presentation details are below:
Title: "Real-world analysis of patients with advanced
gastrointestinal (GI) cancers harboring inactivating TSC1 and TSC2
alterations using the Foundation Medicine genomic
database"
Session Title: Poster Session B: Cancers of the
Pancreas, Small Bowel, and Hepatobiliary Tract
Date/Time: January 19, 2024 – 12:30 –
2:00 pm
Abstract: 558
Presenting Author: Dustin Deming,
MD
Abstract Highlights:
- In a large real-world database of patients with advanced
cancer, 1,898 (1.4%) of the 138,671 patients with GI cancers
harbored at least one known or likely inactivating alteration in
TSC1 or TSC2
- TSC1 and/or TSC2 inactivating alterations were present in 6.8%
of liver cancers, 1.6% of colorectal cancers, and 0.5% of
pancreatic cancers
- Across GI malignancies, genes frequently mutated in tumors with
wild-type TSC1 and TSC2 were similar to genetic mutations
co-occurring in tumors with alterations in TSC1 and/or TSC2
- Most TSC1 and/or TSC2 inactivating alterations in liver and
pancreatic cancers occurred in the context of low TMB and MSS
tumors; whereas increased TMB and MSI signatures were enriched in
colorectal cancer with TSC1 and/or TSC2 alterations
- Limitations of this exploratory, real-world study include the
timing of sampling (at initial diagnosis vs disease progression)
and the absence of clinically matched outcomes data. More research
is needed to understand the clinical and prognostic implications of
these data
- The PRECISION 1 study (NCT05103358) is currently enrolling
patients with solid tumors harboring TSC1 and/or TSC2 inactivating
alterations
Aadi is also presenting Trials-in-Progress (TiP) posters from
its PRECISION 1 and NET clinical studies.
Title: " PRECISION 1: A phase 2, multicenter,
open-label basket trial of nab-sirolimus for malignant solid tumors
harboring pathogenic in activating alterations in TSC1 and
TSC2"
Session Title: Trials in Progress Poster Session B:
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Date/Time: January 19, 2024 – 12:30 –
2:00 pm
Abstract: TPS585
Presenting Author: Dustin Deming,
MD
Title: "A phase 2, study of nab-sirolimus in patients with
well-differentiated and advanced/metastatic neuroendocrine tumors
of the gastrointestinal tract, lunch, or pancreas"
Session
Title: Trials in Progress Poster Session B: Cancers of the
Pancreas, Small Bowel, and Hepatobiliary Tract
Date/Time: January 19, 2024 – 12:30 –
2:00 pm
Abstract: TPS601
Presenting Author: Scott Paulson,
MD
More information can be found on the ASCO GI meeting
website.
About Aadi Bioscience, Inc.
Aadi is a commercial-stage biopharmaceutical company focused on
precision therapies for genetically defined cancers to bring
transformational therapies to cancer patients with mTOR pathway
driver alterations. Aadi received FDA approval and has
commercialized FYARRO® for the treatment of adult
patients with locally advanced unresectable or metastatic malignant
perivascular epithelioid cell tumor (PEComa).
Aadi has also initiated PRECISION1, a Phase 2 tumor-agnostic
registration-intended trial in mTOR inhibitor-naïve malignant solid
tumors
harboring TSC1 or TSC2 inactivating
alterations. More information on the Company's development pipeline
is available on the Aadi website at www.aadibio.com and
connect with us on Twitter and LinkedIn.
Contact:
Marcy
Graham
IR@aadibio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/aadi-bioscience-announces-poster-presentations-at-the-2024-american-society-of-clinical-oncology-asco-gastrointestinal-gi-cancers-symposium-302039765.html
SOURCE Aadi Bioscience